BriaCell announces 1-for-15 share consolidation to maintain Nasdaq listing

BriaCell Therapeutics Corp.

Consolidation ratio: 1 post-consolidation share for every 15 pre-consolidation shares.
Effective date expected January 24, 2025; trading on TSX and Nasdaq from Jan 29, 2025.
No fractional shares issued; fractions cancelled for no consideration.
Convertible securities exercise prices and share counts proportionally adjusted.
Action needed to comply with Nasdaq Capital Market listing requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.